R420
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 50
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.480
- TGF_BETA_SIGNALING+0.380
- ANDROGEN_RESPONSE+0.340
- UV_RESPONSE_DN+0.340
- PANCREAS_BETA_CELLS+0.310
- ANGIOGENESIS+0.250
- MYC_TARGETS_V1+0.230
- KRAS_SIGNALING_UP+0.210
- COMPLEMENT+0.140
- HYPOXIA+0.120
Top 10 suppressed
- E2F_TARGETS-0.320
- MYOGENESIS-0.250
- DNA_REPAIR-0.200
- ESTROGEN_RESPONSE_LATE-0.190
- INTERFERON_ALPHA_RESPONSE-0.180
- MYC_TARGETS_V2-0.180
- IL6_JAK_STAT3_SIGNALING-0.170
- MITOTIC_SPINDLE-0.140
- G2M_CHECKPOINT-0.130
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG601 | — | — | 0.723 |
| 2 | DRR168531 | — | — | 0.703 |
| 3 | MNG643 | — | — | 0.692 |
| 4 | TCGA-D8-A1JA-01A-11R-A13Q-07 | — | C | 0.669 |
| 5 | MNG636 | — | — | 0.667 |
| 6 | SRR6013569 | — | cohortMD2 | 0.642 |
| 7 | TCGA-55-7815-01A-11R-2170-07 | — | cohortMD2 | 0.634 |
| 8 | SRR4195651 | — | — | 0.629 |
| 9 | fb5d10ba-36f3-4236-b8fd-7c057db51039 | — | — | 0.627 |
| 10 | R347 | — | — | 0.624 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.480 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.060 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.030 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.030 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |